0001209191-21-005752.txt : 20210127
0001209191-21-005752.hdr.sgml : 20210127
20210127190009
ACCESSION NUMBER: 0001209191-21-005752
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210125
FILED AS OF DATE: 20210127
DATE AS OF CHANGE: 20210127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RUBINSTEIN JULIE
CENTRAL INDEX KEY: 0001780664
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 21561410
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-25
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780664
RUBINSTEIN JULIE
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
0
1
0
0
President
Common Stock
2021-01-25
4
M
0
15000
6.32
A
15000
D
Common Stock
2021-01-25
4
S
0
3871
65.09
D
11129
D
Common Stock
2021-01-25
4
S
0
1813
65.89
D
9316
D
Common Stock
2021-01-25
4
S
0
8816
67.05
D
500
D
Common Stock
2021-01-25
4
S
0
500
67.79
D
0
D
Common Stock
2021-01-26
4
M
0
15000
6.32
A
15000
D
Common Stock
2021-01-26
4
S
0
10930
64.32
D
4070
D
Common Stock
2021-01-26
4
S
0
3470
65.28
D
600
D
Common Stock
2021-01-26
4
S
0
600
65.90
D
0
D
Stock Option (Right to Buy)
6.32
2021-01-25
4
M
0
15000
0.00
D
2025-06-09
Common Stock
15000
155000
D
Stock Option (Right to Buy)
6.32
2021-01-26
4
M
0
15000
0.00
D
2025-06-09
Common Stock
15000
140000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.49 to 65.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.57 to 66.08, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.57 to 67.56, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.67 to 67.93, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.76 to 64.71, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.76 to 65.50, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.79 to 66.01, inclusive.
The option is fully vested and exercisable.
/s/ Julie Rubinstein by Eric Billings, attorney-in-fact
2021-01-27